Letermovir for Cytomegalovirus Prophylaxis After Lung Transplantation: Hematologic Recovery and Predictors of Switch from Valganciclovir (ISHLT 2026) - Feb 2, 2026 - Abstract #Pub #1473; Pres time: Apr 24, 2026; 04:30 PM - 05:30 PM; Location: Poster Hall; Board #007; "Seven of 39 patients (18%) developed rejection during LTV prophylaxis, yet leukocyte recovery persisted (Figure 1).Conclusion Switching from VGCV to LTV reverses cytopenia without loss of antiviral protection, even amid ongoing immunosuppression. These findings support LTV as a safe, effective CMV prophylaxis alternative in lung transplant recipients with VGCV-induced leukopenia."
Cytomegalovirus Infection • Hematological Disorders • Leukopenia • Transplantation
|
|
D. Vega; B. North; J. Solera; A. Pelaez; J. Salgado; S. Al-Bayati; M. Gil-Barturen; M. Pipkin; P. Cabrera Rios; M. Macek; J. Fernandez; Y. Natori
|